PubMed
Humanin: a novel mitochondrial-derived peptide that protects against cellular stress
Hashimoto Y, Niikura T, Ito Y, et al. Proc Natl Acad Sci USA. 2003
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 52% · Mixed 30% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.025–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 92 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 514 repeat reporters
Published sources linked on the Humanin and IGF-1 DES wiki pages.
PubMed
Hashimoto Y, Niikura T, Ito Y, et al. Proc Natl Acad Sci USA. 2003
PubMed
Mitchell AC, Jiang S, Peterhoff CM, et al. Mol Neurodegener. 2015
PubMed
Hazafa A, Batool A, Ahmad S, et al. Life sciences. 2021
PubMed
Rochette L, Meloux A, Zeller M, et al. Archives of cardiovascular diseases. 2020
PubMed
Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996
PubMed
Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990
PubMed
Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995
PubMed
Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997
PubMed
Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024